Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Mesoporous silica nanoparticles as drug delivery systems for targeted inhibition of Notch signaling in cancer.

Mamaeva V, Rosenholm JM, Bate-Eya LT, Bergman L, Peuhu E, Duchanoy A, Fortelius LE, Landor S, Toivola DM, Lindén M, Sahlgren C.

Mol Ther. 2011 Aug;19(8):1538-46. doi: 10.1038/mt.2011.105. Epub 2011 May 31.

2.

Active targeting of mesoporous silica drug carriers enhances γ-secretase inhibitor efficacy in an in vivo model for breast cancer.

Wittig R, Rosenholm JM, von Haartman E, Hemming J, Genze F, Bergman L, Simmet T, Lindén M, Sahlgren C.

Nanomedicine (Lond). 2014 May;9(7):971-87. doi: 10.2217/nnm.13.62. Epub 2013 Jul 30.

PMID:
23898823
3.

Inhibiting Notch Activity in Breast Cancer Stem Cells by Glucose Functionalized Nanoparticles Carrying γ-secretase Inhibitors.

Mamaeva V, Niemi R, Beck M, Özliseli E, Desai D, Landor S, Gronroos T, Kronqvist P, Pettersen IK, McCormack E, Rosenholm JM, Linden M, Sahlgren C.

Mol Ther. 2016 May;24(5):926-36. doi: 10.1038/mt.2016.42. Epub 2016 Feb 26.

4.

Advances in mesoporous silica nanoparticles for targeted stimuli-responsive drug delivery.

Baeza A, Colilla M, Vallet-Regí M.

Expert Opin Drug Deliv. 2015 Feb;12(2):319-37. doi: 10.1517/17425247.2014.953051. Epub 2014 Nov 25. Review.

PMID:
25421898
5.

Integrated hollow mesoporous silica nanoparticles for target drug/siRNA co-delivery.

Ma X, Zhao Y, Ng KW, Zhao Y.

Chemistry. 2013 Nov 11;19(46):15593-603. doi: 10.1002/chem.201302736. Epub 2013 Oct 2.

PMID:
24123533
6.

Rational targeting of Notch signaling in cancer.

Rizzo P, Osipo C, Foreman K, Golde T, Osborne B, Miele L.

Oncogene. 2008 Sep 1;27(38):5124-31. doi: 10.1038/onc.2008.226. Review.

PMID:
18758481
7.

Blocking the NOTCH pathway can inhibit the growth of CD133-positive A549 cells and sensitize to chemotherapy.

Liu J, Mao Z, Huang J, Xie S, Liu T, Mao Z.

Biochem Biophys Res Commun. 2014 Feb 21;444(4):670-5. doi: 10.1016/j.bbrc.2014.01.164. Epub 2014 Feb 3.

PMID:
24502949
8.

Synthetic lethality through combined Notch-epidermal growth factor receptor pathway inhibition in basal-like breast cancer.

Dong Y, Li A, Wang J, Weber JD, Michel LS.

Cancer Res. 2010 Jul 1;70(13):5465-74. doi: 10.1158/0008-5472.CAN-10-0173. Epub 2010 Jun 22.

9.

Mechanisms and clinical prospects of Notch inhibitors in the therapy of hematological malignancies.

Nefedova Y, Gabrilovich D.

Drug Resist Updat. 2008 Dec;11(6):210-8. doi: 10.1016/j.drup.2008.09.002. Epub 2008 Oct 31. Review.

10.

Alpha-secretase inhibition reduces human glioblastoma stem cell growth in vitro and in vivo by inhibiting Notch.

Floyd DH, Kefas B, Seleverstov O, Mykhaylyk O, Dominguez C, Comeau L, Plank C, Purow B.

Neuro Oncol. 2012 Oct;14(10):1215-26. Epub 2012 Sep 7.

11.

Notch reporter activity in breast cancer cell lines identifies a subset of cells with stem cell activity.

D'Angelo RC, Ouzounova M, Davis A, Choi D, Tchuenkam SM, Kim G, Luther T, Quraishi AA, Senbabaoglu Y, Conley SJ, Clouthier SG, Hassan KA, Wicha MS, Korkaya H.

Mol Cancer Ther. 2015 Mar;14(3):779-87. doi: 10.1158/1535-7163.MCT-14-0228. Epub 2015 Feb 11.

12.

Targeting Notch signaling by γ-secretase inhibitor I enhances the cytotoxic effect of 5-FU in gastric cancer.

Lee HW, Kim SJ, Choi IJ, Song J, Chun KH.

Clin Exp Metastasis. 2015 Aug;32(6):593-603. doi: 10.1007/s10585-015-9730-5. Epub 2015 Jul 2.

PMID:
26134677
13.

Atonal homolog 1 is required for growth and differentiation effects of notch/gamma-secretase inhibitors on normal and cancerous intestinal epithelial cells.

Kazanjian A, Noah T, Brown D, Burkart J, Shroyer NF.

Gastroenterology. 2010 Sep;139(3):918-28, 928.e1-6. doi: 10.1053/j.gastro.2010.05.081. Epub 2010 Jun 2.

14.

Therapeutic approaches to modulating Notch signaling: current challenges and future prospects.

Groth C, Fortini ME.

Semin Cell Dev Biol. 2012 Jun;23(4):465-72. doi: 10.1016/j.semcdb.2012.01.016. Epub 2012 Jan 30. Review.

15.

Enhancing Cellular Uptake and Doxorubicin Delivery of Mesoporous Silica Nanoparticles via Surface Functionalization: Effects of Serum.

Shahabi S, Döscher S, Bollhorst T, Treccani L, Maas M, Dringen R, Rezwan K.

ACS Appl Mater Interfaces. 2015 Dec 9;7(48):26880-91. doi: 10.1021/acsami.5b09483. Epub 2015 Nov 20.

PMID:
26562468
16.

Notch signaling in breast cancer and tumor angiogenesis: cross-talk and therapeutic potentials.

Shi W, Harris AL.

J Mammary Gland Biol Neoplasia. 2006 Jan;11(1):41-52. Review.

PMID:
16947085
17.

Mesoporous silica nanoparticle-based substrates for cell directed delivery of Notch signalling modulators to control myoblast differentiation.

Böcking D, Wiltschka O, Niinimäki J, Shokry H, Brenner R, Lindén M, Sahlgren C.

Nanoscale. 2014;6(3):1490-8. doi: 10.1039/c3nr04022d.

PMID:
24316607
18.

Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence.

Pandya K, Meeke K, Clementz AG, Rogowski A, Roberts J, Miele L, Albain KS, Osipo C.

Br J Cancer. 2011 Sep 6;105(6):796-806. doi: 10.1038/bjc.2011.321. Epub 2011 Aug 16.

19.

Inhibition of Notch signaling reduces the stem-like population of breast cancer cells and prevents mammosphere formation.

Grudzien P, Lo S, Albain KS, Robinson P, Rajan P, Strack PR, Golde TE, Miele L, Foreman KE.

Anticancer Res. 2010 Oct;30(10):3853-67.

PMID:
21036696
20.

Downregulation of Notch pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model.

Efferson CL, Winkelmann CT, Ware C, Sullivan T, Giampaoli S, Tammam J, Patel S, Mesiti G, Reilly JF, Gibson RE, Buser C, Yeatman T, Coppola D, Winter C, Clark EA, Draetta GF, Strack PR, Majumder PK.

Cancer Res. 2010 Mar 15;70(6):2476-84. doi: 10.1158/0008-5472.CAN-09-3114. Epub 2010 Mar 2.

Supplemental Content

Support Center